FINWIRES · TerminalLIVE
FINWIRES

HKG:1779

5 stories mentioning HKG:1779

Every FINWIRES story that references HKG:1779, newest first.

Asia

LongBio Pharma's Seasonal Allergy Drug LP-003 Meets Main Goal of Study

LongBio Pharma's (HKG:1779) seasonal allergic rhinitis treatment LP-003 met the main goal of a phase 3 study, the firm said in a Hong Kong bourse filing Friday.According to LongBio, the late-stage study in China met its pre-specified primary endpoints with "highly statistically and clinically significant" results.The firm enrolled 546 patients in the study, including those who did not achieve satisfactory results with standard treatment.

HKG:1779
Asia

Hong Kong Stocks End Week in Red; Three Firms Make Market Debut

Hong Kong stocks plunged Friday as tensions in the Middle East showed no signs of letting up and investors booked profits ahead of the weekend.The Hang Seng Index fell by around 291.45 points, or roughly 1.2%, to end at 24,961.95, while the Hang Seng China Enterprises Index decreased by 65.28 points, or around 0.8%, to close at 8,436.63.Investment sentiment in Asia was tepid as semiconductor stocks slumped on Wall Street after Broadcom's AI chip sales guidance fell short of market expectations.Investors were cautiously optimistic after U.S. President Donald Trump said that ceasefire negotiations are in their "final" stages, though Iran's foreign minister had earlier described the talks as stalled, according to media reports.Meanwhile, regional investors continue to withdraw capital from Hong Kong in favor of technology bets elsewhere, The South China Morning post reported.According to the report, mainland investors became net sellers last month after selling HK$3.6 billion worth of Hong Kong stocks, the first monthly outflow in three years."Conversations with market participants reveal that regional investors have been selling their positions in Hong Kong to fund purchases of regional tech names in South Korea, Taiwan and Japan," Richard Tang, head equity research analyst for Asia at Julius Baer, was quoted as saying.In corporate news, three firms made their market debut with mixed performances.LongBio Pharma (HKG:1779) shares closed at HK$131.80 each, 37% above their initial public offering price of HK$96.06 in a strong Hong Kong debut.Dajin Heavy Industry (HKG:1081, SHE:002487) remained flat after closing at HK$66.40 per share, matching its IPO price, while Lung Fung Group (HKG:2290) closed at HK$2.81 per share, 45% below its IPO price of HK$5.18 in a tepid Hong Kong debut.

Hang SengHKG:1081HKG:1779HKG:2290SHE:002487
Asia

LongBio Pharma Rises 50% in Hong Kong Trading Debut

LongBio Pharma's (HKG:1779) shares opened 50% above their initial public offering price in a strong Hong Kong debut on Friday morning.The Chinese biopharmaceutical company opened at HK$144.30 per share, well above the offer price of HK$96.06.

HKG:1779
Asia

LongBio Pharma Raises HK$1.3 Billion in Hong Kong IPO Ahead of Debut

LongBio Pharma (HKG:1779) raised HK$1.25 billion in net proceeds from its initial public offering in Hong Kong.The final offer price was set at HK$96.06 per H-share, according to a Thursday after-market filing with the Hong Kong Stock Exchange.The Chinese biopharmaceutical company offered 14.2 million H-shares in the global offering.The Hong Kong public offer was 4,762.58 times subscribed, with a final allocation of 1.4 million shares, representing 10% of the total offering.The international offering was 10.94 times subscribed, with a final allocation of 12.8 million shares, or 90% of the total offering.An over-allocation of 2.1 million shares was made under the global offering.Cornerstone investors, including OrbiMed Genesis, The Biotech Growth Trust, TruMed Innovation Fund, TruMed Master Fund, Shanghai Gaoyi, Wisdomshire Asset Management, Vision Fund 1, and GSC Fund 1, were allotted a combined 7.1 million shares, representing 49.96% of the global offering, according to the filing.LongBio Pharma is set to debut on the Hong Kong bourse on Friday, June 5.

HKG:1779
Asia

LongBio Pharma Launches HK$1.4 Billion Hong Kong IPO

LongBio Pharma (HKG:1779) launched its Hong Kong initial public offering on Thursday, seeking to raise about HK$1.36 billion from the deal.The China-based clinical-stage biopharmaceutical company is offering 14.2 million shares at HK$96.06 per share, according to a Hong Kong bourse filing.The offering comprises 1.4 million shares for Hong Kong investors and 12.8 million shares for international investors, subject to reallocation and the overallotment option.The offer price is expected to be determined by June 2, with allocation results due by June 4, ahead of the company's planned trading debut on June 5.Net proceeds will primarily fund the development and commercialization of the core product, LP-003, and the key product, LP-005, including clinical trials across allergy, autoimmune, and complement-related indications.The funds will also support the development of other pipeline products and R&D platforms, with the remaining earmarked for working capital and general corporate purposes.Sinolink Securities (Hong Kong) is acting as the sole sponsor and the sole sponsor-overall coordinator.Sinolink Securities (Hong Kong), GF Securities (Hong Kong), ABCI Capital, CCB International Capital, Shanxi Securities International, and TradeGo Markets are serving as overall coordinators, joint global coordinators, joint bookrunners, and joint lead managers.ABCI Securities Company is acting as a joint lead manager.

HKG:1779